

CONTACT ADDRESS

nanOPET Pharma GmbH

Luisencarrée

Robert-Koch-Platz 4 • 10115 Berlin • Germany

Tel.: +49 (0)30 89 04 97 40 • Fax: +49 (0)30 89 04 97 499

E-Mail: imaging@nanopet.de

www.nanopet-pharma.com

www.viscover.com

viscover

nanOPET

Research that's more than just state-of-the-art.

MRI CT US OI PET SPECT

Innovative solutions in diagnostic imaging and pharmaceutical nanotechnology

Consulting

Service




Contrast Agents

Technology advancement to benefit your research

As a technology and service provider to the biopharmaceutical industry, nanoPET specializes in the R&D and production of innovative agents for diagnostic imaging. Our customers benefit from the long-standing industry expertise our team has attained in the pharmaceutical development of clinical contrast agents. Nanotechnology is a key element of our business allowing us to offer you materials with unique features.

Viscover™ imaging agents – a landmark in small animal imaging

As animal imaging is rapidly gaining relevance in pharmaceutical research, we are delighted to offer you an exciting portfolio of specialized pre-clinical imaging agents covering the principal imaging modalities – in fact, the first of its kind:

-  **GadoSpin™ and FeraSpin™ contrast agents for MRI**
-  **ExiTron™ contrast agents for CT**
-  **PolySon™ contrast agents for ultrasound**
-  **NiraWave™ contrast agents for optical imaging**

Using innovative (nano-)technologies most of our agents are far ahead of the human clinical routine, yet we provide the clinical standard agents as well. Novel PET and SPECT agents are soon to follow.

Visit our website and get your free copy of the Imaging Guide: www.viscover.com

Consulting and Service tailored to your needs

nanoPET strives to meet customer demand for tailor-made nanopharmaceuticals and imaging agents. Our custom solutions include agent development, pharmaceutical manufacturing as well as experiment design. We are the only company to offer target-specific imaging agents for all modalities. Collaboration opportunities range from pilot studies to long-term partnerships.

The first nanoparticulate tracers for clinical PET

As an addition to its pre-clinical products, nanoPET currently prepares the clinical development of its patented technology platform: inorganic nanoparticulate tracers for cell- and molecular-specific positron emission tomography (PET).

nanoPET - we love your image.

nan**PET**

